ID   SK-GT-5
AC   CVCL_8114
SY   SKGT5
DR   BioSample; SAMN03151916
DR   cancercelllines; CVCL_8114
DR   IARC_TP53; 4080
DR   Wikidata; Q54953663
RX   PubMed=7665247;
RX   PubMed=8334620;
RX   PubMed=20075370;
RX   PubMed=23795680;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a SK-GT-2 derivative (PubMed=20075370). Originally thought to originate from a 67 year old male patient with an esophageal adenocarcinoma.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00368.
CC   Population: Hispanic.
CC   Doubling time: 41 hours (PubMed=8334620).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Caution: TP53 mutation indicated incorrectly as being at p.Asp281Glu (c.843C>G) in PubMed=7665247.
CC   Derived from site: In situ; Stomach, fundus; UBERON=UBERON_0001160.
ST   Source(s): PubMed=20075370
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12,13
ST   D16S539: 11,12
ST   D18S51: 14,15
ST   D21S11: 32.2
ST   D3S1358: 15
ST   D5S818: 10
ST   D7S820: 9,10
ST   D8S1179: 15
ST   FGA: 26
ST   Penta D: 9
ST   Penta E: 15,17
ST   TH01: 8,9
ST   TPOX: 9,12
ST   vWA: 15,18
DI   NCIt; C8398; Gastric fundus carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2194 ! SK-GT-2
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=7665247; DOI=10.1002/ijc.2910640109;
RA   Nabeya Y., Loganzo F. Jr., Maslak P., Lai L., de Oliveira A.R.,
RA   Schwartz G.K., Blundell M.L., Altorki N.K., Kelsen D.P., Albino A.P.;
RT   "The mutational status of p53 protein in gastric and esophageal
RT   adenocarcinoma cell lines predicts sensitivity to chemotherapeutic
RT   agents.";
RL   Int. J. Cancer 64:37-46(1995).
//
RX   PubMed=8334620; DOI=10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L;
RA   Altorki N.K., Schwartz G.K., Blundell M.L., Davis B.M., Kelsen D.P.,
RA   Albino A.P.;
RT   "Characterization of cell lines established from human gastric-esophageal
RT   adenocarcinomas. Biologic phenotype and invasion potential.";
RL   Cancer 72:649-657(1993).
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//